Pancreatic Cancer Clinical Trials & Research at Providence Medical Group
Pancreatic cancer develops in the pancreatic ductal, acinar, and islet
cells. Most pancreatic cancers are adenocarcinoma of pancreatic ductal
(PDA) origin. Pancreatic cancer accounts for about 3 percent of all cancers
in the U.S. Risk factors that can be changed include tobacco use, obesity,
and workplace exposure to certain chemicals.
Providence Medical Group is currently enrolling patients for the following
pancreatic cancer clinical trial:
A Phase II, Open-label, Multi-centre Study to Evaluate Safety, Tolerability,
Efficacy, PK, and Immunogenicity of AZD0901 as Monotherapy and in Combination
with Anti-cancer Agents in Participants with Advanced Solid Tumours Expressing
Claudin 18.2 (CLARITY-PanTumour01)
Treatment agent: AZD0901 is a novel antibody-drug conjugate (ADC) targeting
Claudin (CLDN) 18.2.
Physician:
Ian Anderson, MD
Study Coordinator: Teresa Lund //
teresa.lund@stjoe.org // 707-521-3830
Study Resources:
Study Details | AZD0901 in Participants With Advanced Solid Tumours Expressing
Claudin18.2 | ClinicalTrials.gov
Sponsor: AstraZeneca
Location: Providence Cancer Center, Santa Rosa, CA
A Phase 1b/2, Multicenter, OpenLabel Study of Anti-CEACAM5 Antibody-Drug
Conjugate M9140 in Participants With Advanced Solid Tumors (EMD Serono
MS202329-0010 PROCEADE)
A Randomized Phase II Double-Blind Study of Olaparib versus Placebo Following
Curative Intent Therapy in Patients with Resected Pancreatic Cancer and
a Pathogenic BRCA1, BRCA2 or PALB2 Mutation (PCRC EA2192 Apollo)